{
    "name": "deferoxamine",
    "comment": "Rx",
    "other_names": [
        "Desferal"
    ],
    "classes": [
        "Chelators"
    ],
    "source": "https://reference.medscape.com/drug/desferal-deferoxamine-343722",
    "pregnancy": {
        "common": [
            "There are no adequate and well-controlled studies in pregnant women; administer during pregnancy only if potential benefit justifies potential risk to fetus"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Delayed ossification in mice and skeletal anomalies in rabbits observed after drug administered in daily doses up to 4.5 times the maximum daily human dose; no adverse effects observed in similar studies in rats"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Not known whether drug is excreted in human milk; because many drugs are excreted in human milk, caution should be exercised when administered to a nursing woman"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Known hypersensitivity to deferoxamine or any of its components",
                "Patients with severe renal disease or anuria"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Flushing of the skin, urticaria, hypotension, and shock have occurred when drug administered by rapid intravenous injection; best to administer IM slow SC or IV infusion",
                "Rare cases of mucormycosis, some with a fatal outcome, reported with use; if any of suspected signs or symptoms occur, discontinue treatment; mycological tests should be carried out and appropriate treatment instituted immediately",
                "Adult respiratory distress syndrome, also reported in children described following treatment with excessively high intravenous doses in patients with acute iron intoxication or thalassemia",
                "Increases in serum creatinine (possibly dose-related), acute renal failure, and renal tubular disorders, reported in postmarketing experience; monitor patients for changes in renal function",
                "Severe chronic iron overload may precipitate reversible cardiac function impairment if high doses of Vitamin C (>500 mg/day in adults) are given concomitantly; do not administer Vitamin C to HF patients; wait >1 month after treatment to begin supplemental vitamin C therapy; administer vitamin C only if the patient is receiving deferoxamine regularly, ideally soon after setting up the infusion pump; do not exceed a daily vitamin C dose of 200 mg in adults, given in divided doses; monitor cardiac function closely during such combined therapy",
                "Dialysis patients with aluminum-related encephalopathy may experience neurological dysfunction (seizures), possibly due to an acute increase in circulating aluminum;onset of dialysis dementia may be precipitated; treatment in the presence of aluminum overload may result in decreased serum calcium and aggravation of hyperparathyroidism",
                "Not a substitute for standard measures generally used in iron toxicity (eg, induced emesis, gastric lavage)",
                "Iron overload increases susceptibility of patients to Yersinia enterocolitica and Yersinia pseudotuberculosis infections; treatment may therefpre enhance patient's susceptibility; if it occurs, treatment should be discontinued until infection is resolved",
                "Monitor pediatric patients for body weight and growth every 3 months; high doses and concomitant low ferritin levels associated with growth retardation; after reduction of dose, growth velocity may partially resume to pretreatment rates"
            ],
            "specific": [
                {
                    "type": "Ocular and auditory disturbances",
                    "description": [
                        "Ocular and auditory disturbances reported when therapy administered over prolonged periods of time, at high doses, or in patients with low ferritin levels; in most cases, both ocular and auditory disturbances were reversible upon immediate cessation of treatment",
                        "Visual acuity tests, slit-lamp examinations, funduscopy and audiometry recommended periodically in patients treated for prolonged periods of time; toxicity is more likely to be reversed if symptoms or test abnormalities are detected early  ",
                        "Ocular disturbances observed include",
                        "Blurring of vision; cataracts after prolonged administration in chronic iron overload",
                        "Decreased visual acuity including visual loss, visual defects, scotoma",
                        "Impaired peripheral, color, and night vision; optic neuritis, cataracts, corneal opacities, and retinal pigmentary abnormalities",
                        "Auditory abnormalities reported include",
                        "Tinnitus and hearing loss including high-frequency sensorineural hearing loss"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "betibeglogene autotemcel",
            "description": {
                "common": "betibeglogene autotemcel increases effects of deferoxamine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Discontinue iron chelators at least 7 days before starting conditioning.  Some iron chelators are myelosuppressive. After infusion, avoid use of these iron chelators for 6 months. If iron chelation is needed, consider administration of nonmyelosuppressive iron chelators. Phlebotomy can be used in lieu of iron chelation, when appropriate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aluminum hydroxide",
            "description": {
                "common": "deferoxamine decreases levels of aluminum hydroxide by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Deferoxamine chelates iron; its affinity for other minerals is unknown."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ascorbic acid",
            "description": {
                "common": "deferoxamine, ascorbic acid. Other (see comment). Use Caution/Monitor. \nComment: Ascorbic acid increases the availability of iron for chelation with deferoxamine.  Ascorbic acid should be avoided in pts. with cardiac failure undergoing deferoxamine Tx.  Clinical cardiac monitoring recommended for pts. supplemented with ascorbic acid."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "calcium carbonate",
            "description": {
                "common": "deferoxamine decreases levels of calcium carbonate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Deferoxamine chelates iron; its affinity for other minerals is unknown."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbonyl iron",
            "description": {
                "common": "deferoxamine decreases levels of carbonyl iron by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Deferoxamine chelates iron."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ferric maltol",
            "description": {
                "common": "deferoxamine decreases levels of ferric maltol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Deferoxamine chelates iron."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ferrous fumarate",
            "description": {
                "common": "deferoxamine decreases levels of ferrous fumarate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Deferoxamine chelates iron."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ferrous gluconate",
            "description": {
                "common": "deferoxamine decreases levels of ferrous gluconate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Deferoxamine chelates iron."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ferrous sulfate",
            "description": {
                "common": "deferoxamine decreases levels of ferrous sulfate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Deferoxamine chelates iron."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "iron dextran complex",
            "description": {
                "common": "deferoxamine decreases levels of iron dextran complex by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Deferoxamine chelates iron."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "iron sucrose",
            "description": {
                "common": "deferoxamine decreases levels of iron sucrose by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Deferoxamine chelates iron."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "polysaccharide iron",
            "description": {
                "common": "deferoxamine decreases levels of polysaccharide iron by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Deferoxamine chelates iron."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prochlorperazine",
            "description": {
                "common": "deferoxamine, prochlorperazine.\nEither increases toxicity of the other by Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Synergistic increase in neurological adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rose hips",
            "description": {
                "common": "deferoxamine, rose hips. Other (see comment). Use Caution/Monitor. \nComment: Ascorbic acid increases the availability of iron for chelation with deferoxamine.  Ascorbic acid should be avoided in pts. with cardiac failure undergoing deferoxamine Tx.  Clinical cardiac monitoring recommended for pts. supplemented with ascorbic acid."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium bicarbonate",
            "description": {
                "common": "deferoxamine decreases levels of sodium bicarbonate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Deferoxamine chelates iron; its affinity for other minerals is unknown."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium citrate/citric acid",
            "description": {
                "common": "deferoxamine decreases levels of sodium citrate/citric acid by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Deferoxamine chelates iron; its affinity for other minerals is unknown."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tobramycin inhaled",
            "description": {
                "common": "tobramycin inhaled and deferoxamine both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Avoid concurrent or sequential use to decrease risk for ototoxicity"
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Injection site reactions",
            "percent": "60"
        },
        {
            "name": "eg",
            "percent": "40"
        },
        {
            "name": "localized irritation",
            "percent": null
        },
        {
            "name": "induration",
            "percent": null
        },
        {
            "name": "infiltration",
            "percent": null
        },
        {
            "name": "pain",
            "percent": null
        },
        {
            "name": "erythema",
            "percent": null
        },
        {
            "name": "wheal formation",
            "percent": null
        },
        {
            "name": "eschar",
            "percent": null
        },
        {
            "name": "burning",
            "percent": null
        },
        {
            "name": "swelling",
            "percent": null
        },
        {
            "name": "pruritus",
            "percent": null
        },
        {
            "name": "crust",
            "percent": null
        },
        {
            "name": "vesicles",
            "percent": null
        },
        {
            "name": "local edema",
            "percent": null
        },
        {
            "name": "these may be associated with systemic allergic reactions",
            "percent": null
        },
        {
            "name": "Systemic reactions",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "abdominal pain",
            "percent": null
        },
        {
            "name": "arthralgia",
            "percent": null
        },
        {
            "name": "asthma",
            "percent": null
        },
        {
            "name": "fever",
            "percent": null
        },
        {
            "name": "headache",
            "percent": null
        },
        {
            "name": "myalgia",
            "percent": null
        },
        {
            "name": "nausea",
            "percent": null
        },
        {
            "name": "vomiting",
            "percent": null
        },
        {
            "name": "Cardiovascular reactions",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "hypotension with too rapid IV infusion",
            "percent": null
        },
        {
            "name": "tachycardia",
            "percent": null
        },
        {
            "name": "shock",
            "percent": null
        },
        {
            "name": "Hypersensitivity reactions",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "anaphylactic reaction with or without shock",
            "percent": null
        },
        {
            "name": "angioedema",
            "percent": null
        },
        {
            "name": "generalized rash",
            "percent": null
        },
        {
            "name": "urticaria",
            "percent": null
        },
        {
            "name": "Digestive reactions",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "abdominal discomfort",
            "percent": null
        },
        {
            "name": "diarrhea",
            "percent": null
        },
        {
            "name": "nausea",
            "percent": null
        },
        {
            "name": "vomiting",
            "percent": null
        },
        {
            "name": "Hematologic reactions",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "blood dyscrasia including thrombocytopenia and leucopenia",
            "percent": null
        },
        {
            "name": "Hepatic reactions",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "increased transaminases",
            "percent": null
        },
        {
            "name": "hepatic dysfunction",
            "percent": null
        },
        {
            "name": "Musculoskeletal reactions",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "muscle spasms",
            "percent": null
        },
        {
            "name": "growth retardation and bone changes including metaphyseal dysplasia are common in doses",
            "percent": null
        },
        {
            "name": "mg",
            "percent": null
        },
        {
            "name": "kg",
            "percent": null
        },
        {
            "name": "especially those who begin iron chelation in the first three years of life",
            "percent": null
        },
        {
            "name": "reduced risk if doses are kept to",
            "percent": null
        },
        {
            "name": "mg",
            "percent": null
        },
        {
            "name": "kg",
            "percent": null
        },
        {
            "name": "Nervous System reactions",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "neurological disturbances including dizziness",
            "percent": null
        },
        {
            "name": "peripheral sensory",
            "percent": null
        },
        {
            "name": "motor",
            "percent": null
        },
        {
            "name": "or mixed neuropathy",
            "percent": null
        },
        {
            "name": "paresthesias",
            "percent": null
        },
        {
            "name": "seizures",
            "percent": null
        },
        {
            "name": "exacerbation or precipitation of aluminum",
            "percent": null
        },
        {
            "name": "related dialysis encephalopathy",
            "percent": null
        },
        {
            "name": "Special Senses reactions",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "high",
            "percent": null
        },
        {
            "name": "frequency sensorineural hearing loss and",
            "percent": null
        },
        {
            "name": "or tinnitus are uncommon if dosage guidelines are not exceeded and if dose is reduced when ferritin levels decline",
            "percent": null
        },
        {
            "name": "visual disturbances inlcuding decreased acuity",
            "percent": null
        },
        {
            "name": "blurred vision",
            "percent": null
        },
        {
            "name": "loss of vision",
            "percent": null
        },
        {
            "name": "dyschromatopsia",
            "percent": null
        },
        {
            "name": "night blindness",
            "percent": null
        },
        {
            "name": "visual field defects",
            "percent": null
        },
        {
            "name": "scotoma",
            "percent": null
        },
        {
            "name": "retinopathy",
            "percent": null
        },
        {
            "name": "pigmentary degeneration",
            "percent": null
        },
        {
            "name": "optic neuritis",
            "percent": null
        },
        {
            "name": "and cataracts are rare if dosage guidelines are not exceeded",
            "percent": null
        },
        {
            "name": "Respiratory reactions",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "acute respiratory distress syndrome with dyspnea",
            "percent": null
        },
        {
            "name": "cyanosis",
            "percent": null
        },
        {
            "name": "and",
            "percent": null
        },
        {
            "name": "or interstitial infiltrates",
            "percent": null
        },
        {
            "name": "Very rare generalized rash",
            "percent": null
        },
        {
            "name": "Urogenital reactions including dysuria",
            "percent": null
        },
        {
            "name": "acute renal failure",
            "percent": null
        },
        {
            "name": "increased serum creatinine and renal tubular disorders",
            "percent": null
        },
        {
            "name": "Renal dysfunction",
            "percent": null
        },
        {
            "name": "including renal failure",
            "percent": null
        },
        {
            "name": "monitor patients for changes in renal function",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "increased serum creatinine",
            "percent": null
        }
    ]
}